Table 1.
Demographic and Clinical Information
| Aripiprazole (N=24) | Placebo (N=18) | |
|---|---|---|
| Race | 62% AA, 33% W | 56% AA, 35% W |
| Age (years) | 37.8 ± 8.9 | 36 ± 10.1 |
| Age of Illness Onset (years) | 17.9 ± 7.9 | 20.9 ± 5.8 |
|
Diagnosis Schizophrenia Schizoaffective Disorder Bipolar Disorder |
16 (67%) 7 (29%) 1 (4%) |
13 (72%) 4 (22%) 1 (6%) |
| Educational Level (years) | 12.3 ± 1.7 | 11.5 ± 1.4 |
| Age at Menstruation (years) | 12.1 ± 2.1 | 11.9 ± 2.2 |
| Number of Pregnancies | 1.2 ± 1.7 | 1.7 ± 2.1 |
| Number of Children | 0.8 ± 1.3 | 1.1 ± 1.3 |
| Age at First Sexual Encounter (years) | 14.4 ± 3.4 | 13.6 ± 5.6 |
| Mean Number of Partners | 15.4 ± 25.6 | 7.9 ± 12.9 |
| Current Galactorrhea | 65% | 71% |
| Current Oligo/Amenorrhea | 65% | 65% |
| Current Sexual Dysfunction | 70% | 65% |
| Prevalence of Prolactin-Related Effects | 100% 1, 70% 2, 40% 3 | 100% 1, 71% 2, 29% 3 |
|
Primary Antipsychotic Treatment |
||
| Risperidone | 13 (54%) | 9 (50%) |
| Paliperidone | 5 (21%) | 4 (22%) |
| Haloperidol | 4 (17%) | 2 (22%) |
| Fluphenazine/loxapine | 2 (8%) | 1 (6%) |
| Time on primary antipsychotic (days) | 658.4 ± 741.5 | 812.1 ± 865.8 |
|
Other Medications |
||
| Antidepressants | 12 (50%) | 15 (83%) |
| Mood Stabilizers | 6 (25%) | 5 (28%) |
| Anticholinergic Medications | 6 (25%) | 8 (44%) |
| Oral contraceptives | 1 (4%) | 1 (6%) |
This table presents demographic and clinical information for the DAAMSEL cohortsDemographic Information included for those randomized and exposed to drug > 2 weeks (N=42); Prolactin-related outcomes reported only for those with >8 weeks drug exposure (N=37)For baseline variables there were no significant differences noted in demographic measures, clinical history or medications (p>0.05).